Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating expenses:
Research and development	$ 3,788	$ 7,806	$ 9,859	$ 19,845
General and administrative	4,110	3,057	10,992	8,612
Acquired in-process research and development			164,617
Total operating expenses	7,898	10,863	185,468	28,457
Loss from operations	(7,898)	(10,863)	(185,468)	(28,457)
Other income (expense):
Interest and investment income	35	4	89	231
Other expense, net	(8)	(3)	(42)	(96)
Total other income, net	27	1	47	135
Net loss	(7,871)	(10,862)	(185,421)	(28,322)
Dividend on convertible preferred stock related to beneficial conversion feature and issuance costs			(24,437)
Net loss attributable to common shareholders	$ (7,871)	$ (10,862)	$ (209,858)	$ (28,322)
Net loss per share - basic	$ (0.61)	$ (3.36)	$ (27.81)	$ (9.56)
Net loss per share - diluted	$ (0.61)	$ (3.36)	$ (27.81)	$ (9.56)
Weighted-average common shares outstanding used in net loss per share - basic	12,830,782	3,237,477	7,546,969	2,961,623
Weighted-average common shares outstanding used in net loss per share - diluted	12,830,782	3,237,477	7,546,969	2,961,623